Complications and Economic Burden of Surgery in Chronic Rhinosinusitis With Nasal Polyps: An Observational Cohort Study Using Swedish Register Data
Clinical Otolaryngology · 2025
DOI: 10.1111/coa.70009 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Otolaryngology, 2025. Verfasst von Petter Olsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Ear, Nose, and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Postoperative Complications. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.
Abstract (Originalsprache)
Introduction
There is a lack of comprehensive data on complications following sinus surgery (SS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This study aimed to estimate the prevalence of SS‐related complications in CRSwNP patients and examine patient characteristics, predictors of revision surgery, healthcare use, and associated costs using secondary care data from Swedish registers.
Methods
This observational cohort study used Swedish administrative register data to report patient characteristics and estimate the prevalence and incidence of SS‐related complications among CRSwNP patients. Healthcare resource use (HCRU) and associated costs, the probability of and predictors for revision surgery were assessed.
Results
Out of 9178 CRSwNP patients who underwent SS, 8.5% experienced complications to SS. Asthma was the most frequently observed comorbidity. The probability of revision surgery within 4 years was 12%. Factors such as younger age at index, complications to first surgery, earlier index year, and comorbid asthma were significant predictors for future surgery. Within 4 years of follow‐up, patients undergoing SS showed more HCRU and higher related costs compared to matched general population controls (€13 865 vs. €7088 per person; p < 0.001). Asthma comorbidity, the occurrence of complications, and undergone revision surgery were associated with higher costs.
Conclusion
Overall, this study provides valuable clinical insights into patient characteristics, complications to SS, resource use, and factors related to revision surgery in patients with CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Ear, Nose, and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Quantify Research, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Novartis Finland, Espoo, Finland.
- Novartis Pharma AG, Basel, Switzerland.
- Department of Otorhinolaryngology, Jönköping, Sweden.
ORCID-Profile: Petter Olsson, Christoph Abé, Maija Wolf, Mathias Lilja, Ola Sunnergren, Pernilla Sahlstrand-Johnson
Förderung
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Olsson, P., Abé, C., Wolf, M., Lilja, M., Maio-Twofoot, T., Sunnergren, O., & Sahlstrand-Johnson, P. (2025). Complications and Economic Burden of Surgery in Chronic Rhinosinusitis With Nasal Polyps: An Observational Cohort Study Using Swedish Register Data. Clinical Otolaryngology. https://doi.org/10.1111/coa.70009
Vancouver
Olsson P, Abé C, Wolf M, Lilja M, Maio-Twofoot T, Sunnergren O, et al. Complications and Economic Burden of Surgery in Chronic Rhinosinusitis With Nasal Polyps: An Observational Cohort Study Using Swedish Register Data. Clinical Otolaryngology. 2025. doi:10.1111/coa.70009
BibTeX
@article{Olsson2025,
author = {Olsson, Petter and Abé, Christoph and Wolf, Maija and Lilja, Mathias and Maio-Twofoot, Tina and Sunnergren, Ola and Sahlstrand-Johnson, Pernilla},
title = {Complications and Economic Burden of Surgery in Chronic Rhinosinusitis With Nasal Polyps: An Observational Cohort Study Using Swedish Register Data},
journal = {Clinical Otolaryngology},
year = {2025},
doi = {10.1111/coa.70009}
}
EUVIMED